Compugen Announces Participation in the 2026 Stifel Virtual Oncology Forum

Compugen to Present at the 2026 Stifel Virtual Targeted Oncology Forum

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage company focusing on cancer immunotherapy, has recently announced its participation in the 2026 Stifel Virtual Targeted Oncology Forum. This forum, set to take place on May 19, 2026, from 10:00 to 10:25 AM ET, aims to foster discussions on advancements in oncology treatments. Compugen will leverage this platform to present insights into its innovative research and clinical programs that harness the power of artificial intelligence and machine learning for drug target discovery.

Compugen’s pioneering approach integrates computational methodologies to identify novel therapeutic targets, a commitment reflected in its use of its proprietary Unigen™ platform. This system enables Compugen to forge ahead in the research and development of advanced cancer therapies. The company is known for its extensive pipeline, which includes several clinical-stage programs designed to tackle various forms of cancer effectively.

Among its lead programs are COM701 and COM902. COM701 is positioned as a potential first-in-class anti-PVRIG antibody. It is currently undergoing clinical evaluation for its efficacy in treating solid tumors both as a standalone treatment and in combination with other therapies. COM902, on the other hand, is an anti-TIGIT antibody that aims to enhance the body’s anti-tumor immune response. These candidates not only represent innovative therapeutic approaches but also illustrate Compugen's dedication to enhancing cancer treatments through advanced science.

In addition to these programs, Compugen is conducting a blinded randomized trial named MAIA, which focuses on evaluating the effectiveness of COM701 as a maintenance therapy for relapsed platinum-sensitive ovarian cancer patients. This trial seeks to confirm the potential of COM701 in changing treatment paradigms for ovarian cancer, emphasizing the company’s commitment to improving patient outcomes.

Another noteworthy aspect of Compugen's portfolio is its collaboration with AstraZeneca for the development of rilvegostomig, a bispecific antibody targeting PD-1/TIGIT. This partnership leverages Compugen's proprietary technology to advance clinical trials across various phases, offering promising avenues for cancer treatment enhancements. Additionally, GS-0321 (previously referred to as COM503) is a high-affinity antibody licensed to Gilead that targets the interaction between IL-18 binding protein and IL-18. This compound is currently in Phase 1 trials to assess its safety and efficacy.

The upcoming virtual forum will include a live webcast, accessible through Compugen's Investor Relations webpage, with a replay made available afterward. This initiative not only highlights Compugen’s innovative approach to cancer therapies but also its ongoing commitment to transparency and engagement with investors.

As a publicly traded entity on both Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN, Compugen continues to attract attention from the investment community through its groundbreaking work in cancer immunotherapy. With an early-stage immuno-oncology pipeline that includes various research programs aimed at enhancing anti-cancer immunity mechanisms, the company's efforts represent a significant contribution to the field of oncology.

In summary, Compugen’s participation in the 2026 Stifel Virtual Targeted Oncology Forum stands as an exciting opportunity for the company to showcase its advancements in cancer treatment and foster vital discussions on the future of oncological therapies. This presentation promises to be informative for investors, healthcare professionals, and stakeholders keen on the latest developments in cancer immunotherapy.